Published • loading... • Updated
New trial drug slashes prostate cancer recurrence by almost 60 per cent
The phase 3 trial found 95% of patients stayed recurrence-free at 3.8 years, compared with 88% on standard treatment alone.
Summary by Newcastle Herald
3 Articles
3 Articles
dungogchronicle.com.au+2 Reposted by 2 other sources
New trial drug slashes prostate cancer recurrence by almost 60 per cent
Charlestown's Andrew Henderson beat prostate cancer with radiation and darolutamide, after Tjoining the DASL-HiCaP trial though the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.
Coverage Details
Total News Sources3
Leaning Left2Leaning Right0Center1Last UpdatedBias Distribution67% Left
Bias Distribution
- 67% of the sources lean Left
67% Left
L 67%
C 33%
Factuality
To view factuality data please Upgrade to Premium
